Viral Vectors and Plasmid DNA Manufacturing Market to Reach $4.97 Bn, Globally, by 2027 at 24.9% CAGR: Allied Market Research

News provided by

Oct 26, 2020, 09:00 ET

PORTLAND, Ore., Oct. 26, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral Vectors, and Non-Viral Vectors) and Application (Cancers, Inherited Disorders, Viral Infections and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027." According to the report, the global viral vectors and plasmid DNA manufacturing industry was estimated at $918.37 million in 2019, and is expected to hit $4.97 billion by 2027, registering a CAGR of 24.9% from 2019 to 2027.

Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/2681?reqfor=covid

Drivers, restraints, and opportunities-

Increase in funding for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of the global viral vectors and plasmid DNA manufacturing market. On the other hand, high cost of gene therapies and risk of mutagenesis and other impediments impede the growth to certain extent. However, upsurge in demand for synthetic genes and untapped markets in developing economies are anticipated to pave the way for lucrative opportunities in the industry.

Covid-19 scenario-

To combat the novel corona virus, several viral vectors, nucleic acid-based vaccines and antigen-presenting cells are the in pre-clinical development which, in turn, has boosted the global market.
Also, the fact that viral vectors and plasmid DNA have the potential reduce cost of treatment and help decrease repeated administration of medications is expected to keep the demand for gene therapy constant.

The viral vectors segment to lead the trail by 2027-

Based on product, the viral vectors segment contributed to more than two-thirds of the global viral vectors and plasmid DNA manufacturing market revenue in 2019 and is expected to retain its dominance throughout the forecast period, owing to rise in prevalence of cancer. Simultaneously, the plasmid DNA segment is projected to grow at the fastest CAGR of 26.7% throughout the forecast period. This is due to increase in various applications such as DNA vaccines and gene therapies against numerous infectious and acquired diseases & disorders, such as HIV, malaria, cancer, influenza, and enteric pathogens.

The cancer segment to maintain the lion's share-

Based on application, the cancer segment accounted for more than three-fifths of the global viral vectors and plasmid DNA manufacturing market revenue in 2019 and is expected to rule the roost till 2027, due to increase in prevalence of cancer and requirement for quality drugs and versatile therapies for the treatment. The inherited disorders segment, on the other hand, would portray the fastest CAGR of 27.1% from 2020 to 2027. Rise in incidences of inherited disorders has led to increase in R&D activities for development of therapies which, in turn, fuels the segment growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2681

North America to dominate in terms of revenue-

Based on region, North America generated the major share in 2019, holding nearly half of the global viral vectors and plasmid DNA manufacturing market, owing to the presence of modern healthcare facilities and high prevalence of cancer in the region. At the same time, Asia-Pacific would showcase the highest CAGR of 30.6% from 2020 to 2027. This is due to increase in healthcare expenditure, surge in government initiatives to modernize healthcare infrastructure, and rapid industrialization in the area.

Key players in the industry-

Catalent Pharma Solutions
Fujifilm Holdings Corporation
F. Hoffmann-LA Roche Ltd.
Johnson & Johnson
Sanofi Corporation
4D Molecular Therapeutics
Sirion Biotech GmbH
Voyager therapeutics
Thermo Fisher Scientific, Inc.
Cognate BioServices, Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering impact of Covid-19 over this market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.

Plasma Fractionation Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Cold Plasma Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Platelet Rich Plasma Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

DNA Diagnostics Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

DNA Sequencing Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Prenatal DNA Sequencing Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research